Advanced search
Publication Cover
Clinical Interventions in Aging Volume 4, 2009 - Issue
Submit an article Journal homepage
74
Views
15
CrossRef citations to date
0
Altmetric
Original Research

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Dimitrios A Karagiannis1 Ophthalmiatrio Eye Hospital of Athens, Athens, GreeceCorrespondence[email protected]
,
Ioannis D Ladas2 First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, Greece
,
Efstratios Parikakis1 Ophthalmiatrio Eye Hospital of Athens, Athens, Greece
,
Ilias Georgalas2 First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, Greece
,
Athanasios Kotsolis2 First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, Greece
,
Giorgos Amariotakis1 Ophthalmiatrio Eye Hospital of Athens, Athens, Greece
,
Vasileios Soumplis1 Ophthalmiatrio Eye Hospital of Athens, Athens, Greece
&
Panagiotis Mitropoulos1 Ophthalmiatrio Eye Hospital of Athens, Athens, Greece
 show all
Pages 457-461 | Published online: 26 Nov 2009

Figures & data

Figure 1 Retinal thickness in optical coherence tomography during the 18-month follow-up period.

Figure 1 Retinal thickness in optical coherence tomography during the 18-month follow-up period.

Figure 2 Best-corrected visual acuity during the 18-month follow-up period.

Figure 2 Best-corrected visual acuity during the 18-month follow-up period.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.